The lack of mutations and amplifications in the androgen receptor (AR) gene in mHNPC represents a pivotal difference when comparing these two metastatic forms of PCa, presumably because these mutations in mCRPC can provide adaptive resistance to ADT and AR-targeting agents (ARTAs) [34,39,44,45]. The gene discussed is AR; the disease is posterior cortical atrophy.